Lipid Therapy Timeline

In subjects with prior MI/HLD, Simvastatin reduces mortality (all-cause and CAD-related). 4S Trial

In subjects with HLD and prior MI, pravastatin reduced mortality from CAD compared to placebo. LIPID

In subjects CVD risk, Simvastatin is safe and reduces risk of all-cause mortality and major vascular events. HRS Statin

In subjects with recent ACS, 80mg Atorvastatin reduces CV event rates compared to 40mg pravastatin. Prove-IT TIMI-22

In subjects with stable CAD, HLD, atorva 80 > atorva 10 with greater reduction in CAD-related mortality, non-fatal MI, stroke. TNT

In subjects with CAD (as diagnosed by IVUS), Rosuvastatin 40mg daily reversed atherosclerosis as demonstrated on IVUS. ASTEROID

In subjects with normal LDL, elevated HS-CRP, rosuvastatin 20mg daily reduces the incidence of CV events compared to placebo. JUPITER

In patients with recent ACS, ezetimibe + simvastatin 40mg (moderate-intensity) is associated with a reduction in CV mortality, major CV event, or nonfatal stroke when compared to statin therapy alone. IMPROVE-IT

In patients with higk risk for cardiovascular events, alirocumab + high intensity statin = 62% reduction in LDL, 2% ARR in MACE. ODYSSEY

In patients with CAD and LDL >70 on moderate/high intensity statin, the addition of evolocumab resulted in ARR of 1.5% in MACE at a follow-up of 26 months. There was no overall or CV-specific mortality benefit with evolocumab. FOURIER

In patients with CAD or DM2+risk factors, already on statin therapy, with residual hypertriglyceridemia (fasting triglyceride level 135-499 mg/dL) adding icosapent ethyl = ARR 4.8% in MACE, 0.9% ARR in cardiovascular death at 5 years. REDUCE-IT

In patients with statin-intolerance, bempedoic acid is associated with lower MACE. CLEAR

In patients with NSTEMI, early dose of 80mg atorvastatin reduced the combined endpoint of death, nonfatal MI, cardiac arrest, and ACS requiring hospitalization at 16 weeks. MIRACL